Phase II trial in 94 patients with alopecia areata: deucravacitinib 6 mg once or twice daily vs placebo showed no meaningful difference in SALT score change at week 24 (adjusted differences 1.5 and 8.2) or secondary endpoints; efficacy endpoints were not met.
RCTn = 94
King et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial